[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Ishibashi
Tadashi
T
tadashi- ishibashi@ds-pharma.co.jp
Nishikawa
Hiroyuki
H
Une
Teruaki
T
Nakamura
Hiroshi
H
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy; D065127:Dopamine D2 Receptor Antagonists; D004311:Double-Blind Method; D055808:Drug Discovery; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D058830:Serotonin 5-HT2 Receptor Antagonists; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D065127:Dopamine D2 Receptor Antagonists; D010879:Piperazines; D010880:Piperidines; D058830:Serotonin 5-HT2 Receptor Antagonists; C079310:blonanserin